Fresenius Kabi USA has announced the availability of Levofloxacin in 5% dextrose injection in freeflex containers.
Freeflex is a PVC-free, plasticizer-free, non-DEHP container, which is designed for easy handling and infusing the solutions with enhanced safety, environmental performance in mind.
These containers are available in the global market since 2005 and in the US since 2008.
Fresenius Kabi USA president and CEO John Ducker said, "The introduction of Levofloxacin using the freeflex technology expands our market leading anti-infective business with a ready to use formulation and provides customers with a new choice in serving their patients."
Levofloxacin is a fluoroquinolone antibacterial indicated for use in the treatment of bacterial infections caused by susceptible bacteria, including pneumonia, bronchitis, skin infections, urinary tract infections, prostatitis and anthrax.
Earlier this June, the company received the US Food and Drug Administration (FDA) approval for Levofloxacin in 5% dextrose injection.